Pharma unites against Alameda drug disposal ordinance in US
This article was originally published in SRA
Brand-name and generic drug makers have come together to fight a first-of-its-kind US ordinance in Alameda County, California, that requires pharmaceutical manufacturers to design, implement and pay for a program to collect and dispose of unused prescription pills.
You may also be interested in...
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.